ORIC
ORIC clinical trials: Oric Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Oric Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
ORIC on the catalyst calendar · ORIC registry changes
- Primary completion Mar 2028Sponsor estimatePhase 3NCT07723248A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With...ORIC Pharmaceuticals · Metastatic Castration Resistant Prostate CancerRecruitingORICLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1/Phase 2NCT05315700Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationORIC Pharmaceuticals · Solid TumorsRecruitingORICLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1NCT05413421Study of ORIC-944 in Patients With Metastatic Prostate CancerORIC Pharmaceuticals · Metastatic Prostate CancerRecruitingORICLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT06816992ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCORIC Pharmaceuticals · Solid TumorsRecruitingORICLeadJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 3, 2025ActualPhase 1NCT05227144Study of ORIC-533 in Relapsed or Refractory Multiple MyelomaORIC Pharmaceuticals · Relapsed or Refractory Multiple MyelomaCompletedORICLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2023ActualPhase 1NCT06012721Effect of Food on the Pharmacokinetics of ORIC-114ORIC Pharmaceuticals · Food Effect in Healthy ParticipantsCompletedORICLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 22, 2022ActualPhase 1NCT04033328Study of ORIC-101 in Combination With EnzalutamideORIC Pharmaceuticals · Prostatic NeoplasmsTerminatedORICLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2022ActualPhase 1NCT03928314Study of ORIC-101 in Combination With Anticancer TherapyORIC Pharmaceuticals · Solid TumorTerminatedORICLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 4, 2018ActualPhase 1NCT03835637Single and Multiple Dose Study of ORIC-101 in Adult Healthy SubjectsORIC Pharmaceuticals · Healthy VolunteersCompletedORICLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 18, 2017ActualPhase 1NCT03324555Study of ORIC-101 in Healthy Adult SubjectsORIC Pharmaceuticals · Healthy VolunteersCompletedORICLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner